Navigation Links
Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
Date:1/10/2008

INCHEON, South Korea, Jan. 10 /PRNewswire/ -- Celltrion, Inc., a Korean biopharmaceutical company whose core business is currently contract manufacturing, and CSL Limited, Australia's leading biopharmaceutical company, announced today the signing of an agreement for the development and supply of CSL 360, an experimental monoclonal antibody therapy for the treatment of acute myeloid leukemia (AML). Phase I clinical trials for CSL 360 are currently being conducted by CSL in Australia.

As part of the collaboration, Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical development program for CSL 360 and commercialization of the product, with the potential for a longer term strategic manufacturing relationship between the companies in the future.

"Celltrion and its employees are completely committed to world-class quality in biopharmaceutical manufacturing, to assisting CSL in achieving the successful completion of clinical trials, and to providing manufacturing support for CSL's product commercialization," said Jung-Jin Seo, Celltrion's Chairman and Chief Executive Officer.

"Superior quality biopharmaceutical manufacturing facilities of this type are a scarce commodity in this region and we are delighted to have signed this collaboration to provide CSL with the opportunity to facilitate the clinical development of CSL 360 and potentially other exciting future recombinant protein opportunities," said Dr. Brian McNamee, CSL's Chief Executive Officer.

About Celltrion

Celltrion, established in 2002, is a contract manufacturing organization with a headquarters in Incheon, South Korea. Celltrion, an emerging leader in the biopharmaceutical industry, is dedicated to providing high quality services to accelerate product development, while offering scalable manufacturing capabilities for our clients and business partners. Celltrion is also investing in research and devel
'/>"/>

SOURCE Celltrion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... GAINESVILLE, Fla. , Jan. 23, 2015  HyGreen, Inc., ... distribution agreement and partnership with RCA Medical, a subsidiary ... Africa . Each year, hundreds of ... health care-associated infections as organisms are transmitted from patient ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... , CARTERSVILLE, Ga. ; June 2 ... Women (GASC) – Georgia ,s first fully ... minor gynecological surgeries in a true ... facility specializes in laparoscopic and other highly advanced, ...
... (Nasdaq: FHCO ) announced that it has fulfilled an order for 3.5 million ... World Cup. The 2010 World Cup will take place in The Republic of ... . , , , ... three million tickets to the games, is expected to flood the country with visitors. ...
Cached Medicine Technology:New Georgia Advanced Surgery Center Provides Women Many Unique Benefits 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 2The Female Health Company Receives Order for 3.5 Million FC2 Female Condoms for Distribution at 2010 World Cup 3
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Integrated Medical,Systems, Inc., a medical technology systems integrator ... that it has received,510(k) clearance from the U.S. ... 1000(TM) "suitcase" intensive care unit (ICU)., "FDA ... accomplishment for the,company as we continue to demonstrate ...
... PhD.,co-founder and Chief Scientific Officer of Posit Science, has ... announcement by the Institute,today. Dr. Merzenich is one of ... a highly selective process that recognizes,people who have made ... care, and public health. Election is considered one of ...
... Oct. 13 The 2008 NCPA Digest,sponsored by ... 110th Annual,Convention. The Digest has been published annually ... portrait of the financial state of,independent community pharmacy ... an inside look into how the Medicare Part ...
... Knowledge Sharing among Physicians, MOUNTAIN VIEW, Calif., ... the healthcare IT market, Frost & Sullivan recognizes,Infor-Med, ... Sullivan Award for,Technology Innovation for its novel Praxis(R) ... EMR Knowledge Exchanger., The Praxis(R) EMR system ...
... 13 NeoVista, Inc., presented,yesterday the anatomic ... on choroidal neovascular lesions in an analysis ... 26th Annual Meeting. The,12-month data presented by ... Houston, Texas, demonstrated anatomic improvements on both,angiography ...
... neonatology fellows have been awarded grants designed to ... follow-up care of the premature infant as part ... MedImmune,s commitment to expanding research within pediatric medicine, ... totaling $175,000 in research funding. The five recipients ...
Cached Medicine News:Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives FDA Clearance for World's First 'Suitcase' Intensive Care Unit 3Health News:Merzenich Elected to Institute of Medicine 2Health News:Merzenich Elected to Institute of Medicine 3Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 2Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 3Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 2Health News:Frost & Sullivan Awards Infor-Med for its Electronic Medical Record Technology 3Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 2Health News:NeoVista Presents Anatomic Outcomes of Novel Wet AMD Therapy at 2008 American Society of Retina Specialists Meeting 3Health News:MedImmune grants 5 new fellowships to help expand premature infant follow-up care research 2
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: